Fig. 5

Circ-Ntrk2 sponges miR-296-5p to promote pulmonary vascular remodelling and PAH. a All treatment groups received si-circ-Ntrk2 or miR-296-5p antagomir injections twice weekly for modelling for 21 days. b Echocardiographic measurements and images illustrating pulmonary artery acceleration time (PAAT) and pulmonary arterial velocity time integral (PAVTI) in the NOR, HYP, HYP + SI-NC + ANT-NC, HYP + SI + ANT-NC, and HYP + SI + ANT groups are shown (n = 5). c Right ventricular systolic pressure (RVSP) and the right ventricle (RV)/left ventricle (LV) + septum (S) weight ratio in the NOR, HYP, HYP + SI-NC + ANT-NC, HYP + SI + ANT-NC, and HYP + SI + ANT groups (n = 5). d Analysis of pulmonary artery remodelling was performed using H&E and immunofluorescence. e Detection of collagen deposition around blood vessels using Masson staining (up) (n = 5) and H&E staining of myocardial cells in right ventricular wall (bottom) (n = 5). f Analysis of PCNA (proliferating cell nuclear antigen) and cyclin D1 expression in the lung tissues (n = 5) and PASMCs (n = 6). The gel or blot images have been cropped and the complete images have been submitted separately (Additional file 4). g EdU in PASMCs (n = 6). h CCK-8 assay in PASMCs (n = 6). All values are presented as the mean ± SD. *P < 0.05, **P < 0.01